The Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report
for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in …

Background Dupilumab, a fully human monoclonal antibody that blocks the shared receptor
component for interleukin-4 and interleukin-13, key and central drivers of type 2 …

Chronic obstructive pulmonary disease (COPD) is a major global health problem that is
poorly treated by current therapies as it has proved difficult to treat the underlying …

Background The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–
directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with …

Background Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity
and mortality worldwide. COPD exacerbations are associated with a worsening of lung …

Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with a
significant mortality, health and economic burden. Their diagnosis, assessment and …

Chronic obstructive pulmonary disease (COPD) and atherosclerosis are chronic irreversible
diseases, that share a number of common causative factors including cigarette smoking …

The pathology and impact of chronic obstructive pulmonary disease (COPD) results from an
abnormal inflammatory process resulting in tissue damage with ineffective repair in …

Background Treatment with systemic corticosteroids in patients with acute exacerbations of
chronic obstructive pulmonary disease (COPD) is associated with debilitating adverse …